#AAN2018 — NP001 Fails to Improve Disease Severity, Pulmonary Function in ALS Patients, Phase 2 Trial Shows
#AAN2�18 - NP��1 Fails to Improve ALS Disease Severity in Phase 2 Trial
NP001 probably generated more interest among ALS patients than any product in history.